Abstract: The present disclosure relates to a composition for discriminating the species Lactobacillus acidophilus, which enables microorganisms belonging to the species Lactobacillus acidophilus to be discriminated, detected and identified simply, quickly and accurately from a target sample. Therefore, the present disclosure can be effectively used in the development of fermented milk, baby food, dairy products, livestock feed, cosmetics, health supplements, drugs for intestinal disorders, raw materials, etc. using the Lactobacillus acidophilus sp. strain.

Abstract: The present invention relates to a prebiotic composition, a composition for improving gut microorganisms, a composition for improving gut health or gut function, a composition for alleviating, preventing, or treating inflammatory bowel disease or leaky gut syndrome, or a composition for alleviating, preventing, or treating obesity or metabolic disease, which each comprise a molokhia extract or a molokhia polymer fraction as an active ingredient to induce the proliferation of beneficial intestinal bacteria and to improve, prevent, or treat gut heath or gut function. In addition, the composition comprising a molokhia extract or a molokhia polymer fraction as an active ingredient can alleviate, prevent, or treat bowel disease or leaky gut syndrome.

Abstract: The present invention relates to: a novel Lactobacillus intestinalis YT2 strain (deposition number: KCCM11812P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus intestinalis comprising the novel strain. The present inventors have established an animal model for menopause through ovariectomy, confirmed changes of the distribution of intestinal microorganisms by the model, identified and isolated a novel Lactobacillus intestinalis strain among lactic acid bacteria of which the distribution is significantly reduced in the menopausal model, and confirmed effects, by means of the novel strain and previously reported Lactobacillus intestinalis strains, of alleviating menopausal symptoms, such as the inhibition of an increase in body fat, the inhibition of a decrease in bone mineral density, the inhibition of an increase in the pain sensitivity, and the alleviation of depression.

Abstract: The present invention relates to: a novel Lactobacillus intestinalis YT2 strain (deposition number: KCCM11812P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus intestinalis comprising the novel strain. The present inventors have established an animal model for menopause through ovariectomy, confirmed changes of the distribution of intestinal microorganisms by the model, identified and isolated a novel Lactobacillus intestinalis strain among lactic acid bacteria of which the distribution is significantly reduced in the menopausal model, and confirmed effects, by means of the novel strain and previously reported Lactobacillus intestinalis strains, of alleviating menopausal symptoms, such as the inhibition of an increase in body fat, the inhibition of a decrease in bone mineral density, the inhibition of an increase in the pain sensitivity, and the alleviation of depression.

Abstract: The present disclosure relates to a composition for discriminating the species Lactobacillus acidophilus, which enables microorganisms belonging to the species Lactobacillus acidophilus to be discriminated, detected and identified simply, quickly and accurately from a target sample. Therefore, the present disclosure can be effectively used in the development of fermented milk, baby food, dairy products, livestock feed, cosmetics, health supplements, drugs for intestinal disorders, raw materials, etc. using the Lactobacillus acidophilus sp. strain.

Abstract: The present invention relates to: a novel Lactobacillus intestinalis YT2 strain (deposition number: KCCM11812P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus intestinalis comprising the novel strain. The present inventors have established an animal model for menopause through ovariectomy, confirmed changes of the distribution of intestinal microorganisms by the model, identified and isolated a novel Lactobacillus intestinalis strain among lactic acid bacteria of which the distribution is significantly reduced in the menopausal model, and confirmed effects, by means of the novel strain and previously reported Lactobacillus intestinalis strains, of alleviating menopausal symptoms, such as the inhibition of an increase in body fat, the inhibition of a decrease in bone mineral density, the inhibition of an increase in the pain sensitivity, and the alleviation of depression.

Abstract: Provided is a novel Lactobacillus acidophilus YTI strain (deposition number: KCCM 11808P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus acidophilus comprising the novel strain.

Abstract: The present invention relates to a prebiotic composition, a composition for improving gut microorganisms, a composition for improving gut health or gut function, a composition for alleviating, preventing, or treating inflammatory bowel disease or leaky gut syndrome, or a composition for alleviating, preventing, or treating obesity or metabolic disease, which each comprise a molokhia extract or a molokhia polymer fraction as an active ingredient to induce the proliferation of beneficial intestinal bacteria and to improve, prevent, or treat gut heath or gut function. In addition, the composition comprising a molokhia extract or a molokhia polymer fraction as an active ingredient can alleviate, prevent, or treat bowel disease or leaky gut syndrome.

Abstract: The present invention relates to: a novel Lactobacillus intestinalis YT2 strain (deposition number: KCCM11812P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus intestinalis comprising the novel strain. The present inventors have established an animal model for menopause through ovariectomy, confirmed changes of the distribution of intestinal microorganisms by the model, identified and isolated a novel Lactobacillus intestinalis strain among lactic acid bacteria of which the distribution is significantly reduced in the menopausal model, and confirmed effects, by means of the novel strain and previously reported Lactobacillus intestinalis strains, of alleviating menopausal symptoms, such as the inhibition of an increase in body fat, the inhibition of a decrease in bone mineral density, the inhibition of an increase in the pain sensitivity, and the alleviation of depression.

Abstract: Provided is a novel Lactobacillus acidophilus YTI strain (deposition number: KCCM 11808P); and a composition for preventing, alleviating, or treating menopause, comprising, as an active ingredient, Lactobacillus acidophilus comprising the novel strain.